Dr. Shalem’s research focuses on translational target discovery for a range of neurodegenerative diseases. He combines technology development of large-scale CRISPR-based perturbation screens with application of such technology together with additional genomic approaches.
Dr. Davidson works to understand the molecular basis of childhood onset neurodegenerative diseases and the development of gene and small molecule therapies for treatment. She also focuses on how noncoding RNAs participate in neural development and neurodegenerative disease processes, and how they can be harnessed for therapies.
Dr. Song works to elucidate the cellular and molecular basis governing the formation, maintenance, and function of neural circuits under physiological and pathological conditions, using both Drosophila and mammalian models.
Dr. Akizu's research focuses on cerebellar ataxias and motoneuron disorders, with the specific goals of uncovering the particularities of these neuronal types, understanding disease mechanisms, and exploring treatment options.
Dr. Waldman works to understand metrics to quantify disease burden in acquired and genetic neurologic disorders that affect the white matter of the brain. She also focuses on clinical trial methodology to bring novel therapies to neurodegenerative diseases.
Dr. Smith is a laboratory animal medicine veterinarian. As Technical Director of the CCMT Comparative Medicine Services Core, he helps guide promising therapeutics and devices from discovery and developmental studies through nonclinical studies.